SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. SY-LB-35 can stimulate significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle. SY-LB-35 stimulates canonical Smad and non-canonical PI3K/Akt , ERK , p38 and JNK intracellular signaling pathways In Vitro SY-LB-35 (0.01-1000 μM; 24 h) stimulates significant increases in cell number and cell viability in the C2C12 myoblast cell line. SY-LB-35 (0.01-10 μM; 30 min or 15 min) stimulates Smad phosphorylation and nuclear translocation, activates the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulates the phosphorylation and activation of PI3K in the C2C12 cells. SY-LB-35 (0.01-10 μM; 24 h) causes the cell cycle shifting to S and G2/M phases in the C2C12 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: C2C12 cells Concentration: 0.01, 0.1, 1, 10, 100 and 1000 μM Incubation Time: 24 h Result: Stimulated significant increases in cell number and cell viability. Western Blot AnalysisCell Line: C2C12 cells Concentration: 0.01, 0.1, 1 and 10 μM Incubation Time: 30 or 15 min Result: Stimulated Smad phosphorylation and nuclear translocation, activated the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulated the phosphorylation and activation of PI3K in the C2C12 cells. Cell Cycle AnalysisCell Line: C2C12 cells Concentration: 0.01, 0.1, 1 and 10 μM Incubation Time: 24 h Result: Caused the cell cycle shifting to S and G2/M phases. Form:Solid IC50& Target:BMP